HOME >> BIOLOGY >> NEWS
International study findings link acne-like rash to effectiveness of new targeted cancer treatment

Geneva, Switzerland: Acne is not a condition that anyone would welcome under normal circumstances, but an international study of a new targeted cancer treatment cetuximab has shown that patients who developed an acne-like rash responded better to the treatment than those who did not.

Professor Eric Van Cutsem told a news briefing today (Thursday 30 September) at the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics that a trial, conducted in Belgium and the USA, had demonstrated that the more severe the rash the better the patients' tumours had responded to the treatment and the longer was their median survival.

Professor Van Cutsem, who is head of the Digestive Oncology Unit and Professor of Medicine at University Hospital Gasthuisberg in Leuven, said 346 patients with advanced colorectal cancer were treated in the study in Leuven and other Belgian and U.S. centres.

All the patients had metastatic cancer and had failed to respond to at least two prior chemotherapy regimens, although all still had a reasonable quality of life, either being fully active or at least still able to carry out light work.

Cetuximab, also known as Erbitux, is a new targeted treatment a monoclonal antibody designed to home in selectively on a protein called the epidermal growth factor (EGFR). EGFR is found on the surface of some cells and plays a role in regulating cell growth. Cetuximab interferes with the growth of cancer cells by binding to EGFR. It is approved by the Food and Drug Administration in the USA for use with the cancer drug irinotecan for colorectal cancer that has failed other treatments. It is also the first monoclonal antibody targeting EGFR to have gained marketing authorisation in Europe and is now being evaluated in first-line treatment of colorectal cancer, with promising results.

Professor Van Cutsem said that the acne-like rash was also a side effect of other EGFR inhibitors but it was not
'"/>

Contact: Margaret Willson
m.willson@mwcommunications.org.uk
41-227-612-205
European Organisation for Research and Treatment of Cancer
30-Sep-2004


Page: 1 2

Related biology news :

1. USAID, Conservation International & Starbucks launch Conservation Coffee Alliance in Central America
2. ConocoPhillips & Conservation International launch Biodiversity Action Plan in Venezuela
3. A room with a view for the International Space Station: Completion of the cupola observation module
4. International symposium on nutritional genomics
5. First International Scientific Conference on Childhood Leukaemia
6. 1st International Conference on Cell Therapy for Cardiovascular Disease
7. International research conferences at the Villa Vigoni
8. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
9. STN International launches Derwent World Patents Index First View
10. Media invited to attend International Society For Heart & Lung Transplantation meeting April 21-24
11. International critical care doctors release first-ever guidelines for sepsis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2020)... ... July 08, 2020 , ... ... and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • 1:30 ... study, but what is the most effective way to complete one? Will the ...
(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, a global leader ... Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan. ... in Kakegawa, the new 60,000-square-foot facility will provide customers with flexible clinical supply ...
(Date:6/23/2020)... (PRWEB) , ... June 23, ... ... provider of gene-to-protein and monoclonal antibody development services, today announced that the ... products and services to the pharmaceutical, diagnostics, and research industries. The decision ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver this ... the only technology of its kind on the market and we were pleased that ... protective capacity of traditional cultured ingredients, creating a natural way to extend the shelf ...
(Date:7/18/2020)... (PRWEB) , ... July 17, 2020 , ... ... global consulting firm for the life sciences and food industries, is pleased to ... Director of Clinical Research – Business Development. , Charles is an accomplished and ...
(Date:7/10/2020)... ... July 09, 2020 , ... PathSensors Inc., ... has expanded the company’s exclusive license to include clinical applications for CANARY™ ... market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., ... hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of ...
Breaking Biology Technology:
Cached News: